RHOA and Urinary incontinence: In another study, application of estrogen, raloxifene, and levormeloxifene to isolated urethral smooth muscle cells was shown to have a dose-dependent reduction in the expression of RhoA, Rock-I, Rock-II, and p-MLC molecules, which are Rho-kinase signal transduction molecules.[8] The Rho-kinase signaling pathway has a key role in controlling the contraction mechanisms of many smooth muscle cells.[9] For this reason, it can be postulated that estrogen, raloxifene, and levormeloxifene cause urinary incontinence by reducing urethral resistance.